NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph
This article was originally published in The Tan Sheet
Executive Summary
NBTY is predicting a rebound of the current stagnant supplement market as the baby boomer generation continues to enter the "vitamin age.
You may also be interested in...
Sales & Earnings In Brief
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...
Sales & Earnings In Brief
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...
Sales & Earnings In Brief
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...